Designing to Implement Genomics Informed ASCVD Risk Assessment: Patient and Clinician Perspectives about Identifying and Managing the Underlying Causes of Severe Hypercholesterolemia
Kelly MorganiD, Gemme Campbell‐SalomeiD, Zachary M. SalvatiiD, Muki Kunnmann, Dylan CawleyiD, Lauren H. CarriD, Laura Ceballos, Samuel S. GiddingiD, Eimear E. KennyiD, Amy KontorovichiD, Tara Naib, Matthew T. OetjensiD, Vikas Rao PejaveriD, Sabrina A. SuckieliD, Matthew Ian TomeyiD, Laney K. JonesiD, Miranda L. G. HallquistiD
Abstract
IntroductionSevere hypercholesterolemia has four primary causes: monogenic familial hypercholesterolemia (FH), polygenic hypercholesterolemia (PRS), severely elevated Lp(a) concentration, and hypercholesterolemia due to environmental/lifestyle/behavioral factors (i.e., no known genetic etiology). Here, we explore patient and clinician perspectives about the identification and management of each of these causes. MethodsPatients with severe hypercholesterolemia with a primary language of English or Spanish and clinicians (primary care, genetic counseling, cardiology) across two health systems (Geisinger, Mount Sinai) participated in semi-structured interviews. Analysis was completed using an a priori codebook informed by Proctors implementation outcomes to identify themes influencing the identification and management of the underlying causes of severe hypercholesterolemia. ResultsA total of 28 patients and 25 clinicians participated. Patients emphasized the importance of receiving results directly from their clinician, requested take-home resources that mirrored the information from their clinician, were motivated to seek multidisciplinary care, and anticipated all results would be actionable, but that high-risk PRS and elevated Lp(a) may require more support (e.g., specialists, education) to act on. Clinicians stressed the importance of integrating workflows (e.g., test ordering) with the electronic health record, highlighted LDL-C levels and multidisciplinary care coordination as key to management, explained how they would tailor care to individual patients, and expressed a more limited understanding of Lp(a) and PRS result types based on their clinical experiences and, therefore, hesitation about the recommended clinical actions. ConclusionsPatients and clinicians identified complementary determinants influencing the identification and management of the underlying cause of severe hypercholesterolemia. Participants welcomed risk information and requested a higher level of informational support and specialty expertise to appropriately manage high Lp(a) and PRS results. Integrating genomic information into risk assessments will require a partnership between general practitioners and specialists to provide a multidisciplinary approach to the identification and management of the underlying causes of severe hypercholesterolemia.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Population genomic screening leads to improved lipid management in patients with familial hypercholesterolemia
Matthew E. Levy, Kelly M. Schiabor Barrett, … Catherine A. Hajek·Circulation Genomic and Precision MedicinePeer-reviewed·Nov 5, 2025
- Genetic Testing Preferences and Intentions in U.S. Patients with Clinically Diagnosed Familial Hypercholesterolemia
Hannah Wand, Amy Curry Sturm, … William M. P. Klein·Journal of Genetic CounselingPeer-reviewed·Nov 25, 2019
- Polygenic Hyperlipidemias and Coronary Artery Disease Risk
Pietari Ripatti, Joel T Rämö, … Samuli Ripatti·AtherosclerosisPeer-reviewed·Aug 1, 2017
- Association of polygenic risk scores with low-density lipoprotein cholesterol levels and control: findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
Christina G. Selkirk, Tamar Sofer, … Maria Argos·medRxiv·Sep 20, 2026
- Molecular Screening of Familial Hypercholesterolemia in the Icelandic Population
Greg Kellogg, Bolli Þórsson, … Óscar Puig·bioRxiv·Sep 27, 2018
- Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Historical Cholesterol Exposure
Shoa L. Clarke, Catherine Tcheandjieu, … Themistocles L. Assimes·Circulation Genomic and Precision MedicinePeer-reviewed·Feb 10, 2022